### 59. calls for the reinforcement and diversification of the supply chain , in particular that of cancer drugs , within the eu , close monitoring of medicine tensions and shortages , and the creation of a strategic stockpile of such medicines; ### 59. calls for the reinforcement and diversification of the supply chain , in particular that of cancer drugs , within the eu , close monitoring of medicine tensions and shortages at eu level , and the creation of a strategic stockpile of such medicines; urges the commission , in the context of the eu public procurement directive 2014/24/eu , to develop guidelines to support public procurement practices in the pharmaceutical field for cancer drugs , not relying exclusively or prominently on the criterion of price , in order to foster the sustainability of the supply chain and the resilience of the national health systems , and to avoid a delocalization aimed at reducing the costs of manufacturing;


### 59. calls for the reinforcement and diversification of the supply chain , in particular that of cancer drugs , within the eu , close monitoring of medicine tensions and shortages , and the creation of a strategic stockpile of such medicines; ### 59. calls for the reinforcement and diversification of the supply chain , in particular that of cancer drugs , within the eu , close monitoring of medicine tensions and shortages , the strengthening of stocks' transparency at a national level , the establishment of an alert system notifying the growing risks of shortages , and the creation of a strategic stockpile of such medicines;


### 61. considers that member states should converge on the evaluation of medical technologies; welcomes , therefore , the provisional agreement on the health technology assessment (hta) regulation reached by the european parliament and the council on 22 june 202128 to support harmonised access to innovative cancer diagnosis and treatments; ### 61. considers that member states should converge on the evaluation of medical technologies; welcomes , therefore , the provisional agreement on the health technology assessment (hta) regulation reached by the european parliament and the council on 22 june 202128 to support harmonised access to innovative cancer diagnosis and treatments; encourages more equitable access to medicines for patients across europe by increasing the quality and efficiency of decision-making process; calls on member states to intensify the close european cooperation on joint clinical assessments to use hta resources more effectively after the pandemic and create a viable framework;


### 61. considers that member states should converge on the evaluation of medical technologies; welcomes , therefore , the provisional agreement on the health technology assessment (hta) regulation reached by the european parliament and the council on 22 june 202128 to support harmonised access to innovative cancer diagnosis and treatments; ### 61. considers that member states should converge on the evaluation of medical technologies; welcomes , therefore , the provisional agreement on the health technology assessment (hta) regulation reached by the european parliament and the council on 22 june 202128 to support harmonised and faster access to innovative cancer diagnosis and treatments;


### 62. insists on the need to ensure equal access to affordable drugs , in particular cancer drugs , within the eu; calls for collective negotiation on the price of medicines with pharmaceutical industries , as per the beneluxa initiative on pharmaceutical policy and the valetta declaration; considers that pharmaceutical companies should respect conditionalities on charging an affordable price for medicines developed in the framework of publicly funded research; ### 62. insists on the need to ensure equal access to affordable drugs , in particular cancer drugs , within the eu; calls on member states to consider joint price negotiation with pharmaceutical industries , as per the beneluxa initiative on pharmaceutical policy and the valetta declaration; considers that pharmaceutical companies should respect conditionalities on charging an affordable price for medicines developed in the framework of publicly funded research;


### 63. strongly advocates the extension of joint procurement procedures for cancer medicines to improve affordability and access to cancer treatments at eu level; ### 63. strongly advocates the extension of joint procurement procedures , especially for (ultra)rare types , paediatric and novel cancer medicines and treatments to improve affordability and access to cancer treatments at eu level; highlights that joint public procurement should not hinder patient access , medical innovation or competition;


### 63. strongly advocates the extension of joint procurement procedures for cancer medicines to improve affordability and access to cancer treatments at eu level; ### 63. strongly advocates the extension of joint procurement procedures for cancer medicines , especially in times of health crises , to counter shortages and improve affordability and access to cancer treatments at eu level; notes that the procedures should improve response times and be transparent;


### 63. strongly advocates the extension of joint procurement procedures for cancer medicines to improve affordability and access to cancer treatments at eu level; ### 63. calls for assessing the possibility for the extension of joint procurement procedures for cancer medicines to improve affordability and access to cancer treatments at eu level; calls on the commission to make an assessment of the icu joint procurement initiative and take the lesson learned to improve this tool; considers that this should not impact pre-existing contractual agreements with suppliers of medical countermeasures and should be carried out in accordance with directive 2014/24/eu on public procurement1a in a transparent manner , while respecting the following conditions: the procurement process , criteria , timelines , specifications , and formalities must be transparent and workable; a preliminary consultation phase involving potential participating manufacturers must take place; clear volume commitments irrespective of the selected supply modality must be ensured;


### 64. calls for a review of data exclusivity in the authorisation process of medicines29 , i.e. the period of time within which the marketing authorisation holder of a medicine enjoys exclusive access to the results of preclinical tests and clinical trials , so that compulsory licensing can allow for the market entry of cancer treatments in the event of a health crisis (such as the covid-19 crisis) or to overcome the rising cost of specific treatments; ### 64. calls on the commission to support a regulatory framework which strengthens incentives for rare cancer treatment in the eu to effectively address existing shortcomings; underlines that the patent systems all over the world are drafted in a way that for a specific period of time , i.e. only for the duration of the patent , the inventor is allowed to commercially exploit its patent , whereas thereafter the invention can be freely exploited by anyone; calls on the commission to develop new targeted incentives to ensure equitable access to cancer medicines also in areas where the development of products would otherwise not be sustainable;


### 65. calls on the commission to submit a proposal for the revision of directive 89/105/eec on the transparency of measures regulating the prices of medicinal products30 in order to ensure effective controls and full transparency of the procedures used to determine the price and reimbursement of the cost of medicines , in particular cancer medicines , in member states; calls for pharmaceutical companies to provide information on financing with public resources , as well as on the tax benefits and subsidies they have received; requests that the calculation of drug costs should take into account the use of public funds; calls on the european medicines agency (ema) to increase the number of audits in order to assess pharmaceutical companies’ compliance with the requirements on transparency; ### 65. calls on the commission and member states to support pricing models based on real production costs , innovation and value to patients; calls also on the commission to investigate novel pricing and payment models and their possible impact on patient access to innovative medicines , in particular cancer medicines;


### 66. notes that huge advances in biology have revealed that cancer is an umbrella term for more than 200 diseases , and that precision or personalised medicine can be made available through the drug targeting of various mutations; considers that precision or personalised medicine , consisting of a treatment choice based on individual tumour biomarkers , is a promising way to improve cancer treatment; encourages member states , therefore , to promote the implementation of regional molecular genetics platforms and facilitate equal and rapid access to personalised treatment for patients; ### 66. notes that huge advances in biology have revealed that cancer is an umbrella term for more than 200 diseases , and that precision or personalised medicine can be made available through the drug targeting of various mutations; considers that precision or personalised medicine , consisting of a treatment choice based on individual tumour biomarkers , is a promising way to improve cancer treatment; encourages member states , therefore , to develop personalised medicine across the eu through cooperation between member states and data interoperability , to promote the implementation of regional molecular genetics platforms and facilitate equal and rapid access to personalised treatment for patients;


### 66. notes that huge advances in biology have revealed that cancer is an umbrella term for more than 200 diseases , and that precision or personalised medicine can be made available through the drug targeting of various mutations; considers that precision or personalised medicine , consisting of a treatment choice based on individual tumour biomarkers , is a promising way to improve cancer treatment; encourages member states , therefore , to promote the implementation of regional molecular genetics platforms and facilitate equal and rapid access to personalised treatment for patients; ### 66. notes that huge advances in biology have revealed that cancer is an umbrella term for more than 200 diseases , and that precision or personalised medicine can be made available through the drug targeting of various mutations; considers that precision or personalised medicine , consisting of a treatment choice based on individual tumour biomarkers , is a promising way to improve cancer treatment; encourages member states , therefore , to increase the awareness of personalised medicine among healthcare professionals and patients , to promote the implementation of regional molecular genetics platforms and facilitate equal and rapid access to personalised treatment for patients;


### 67. calls for the full and rapid application of regulation (eu) no 536/2014 of 16 april 2014 on clinical trials on medicinal products for human use31 ; considers that the application of the regulation would facilitate the launch of large clinical trials carried out in a harmonised , efficient and coordinated manner at european level in order to facilitate research into cancer drugs and improve cancer patients’ and their families’ quality of life; ### 67. calls for the full and rapid application of regulation (eu) no 536/2014 of 16 april 2014 on clinical trials on medicinal products for human use31 ; considers that the application of the regulation would facilitate the launch of large clinical trials carried out in a harmonised , efficient and coordinated manner at european level in order to facilitate research into cancer drugs and improve cancer patients’ and their families’ quality of life; urges for a fresh review of opportunities to reduce the bureaucracy associated to clinical trials , as well as long term learning from the covid-19 pandemic on future forms of international trial cooperation and information-sharing;


### 68. calls for a more sustainable environment for conducting research into the repurposing of medicines for cancer treatment and for the creation of an additional project that uses high-performance computing to rapidly test existing molecules and new drug combinations , starting with treatment for cancers with a poor prognosis and rare cancers; ### 68. calls for a more sustainable environment , including financial support for conducting research into the repurposing of medicines for cancer treatment , especially performed by third parties with no commercial intent and for the creation of an additional project that uses high-performance computing to rapidly test existing molecules and new drug combinations , starting with high unmet needs , treatment for cancers with a poor prognosis and rare cancers; suggests an eu cancer policy goal to double the survival rate for cancers with poor prognosis to connect across eu related initiatives;


### 68. calls for a more sustainable environment for conducting research into the repurposing of medicines for cancer treatment and for the creation of an additional project that uses high-performance computing to rapidly test existing molecules and new drug combinations , starting with treatment for cancers with a poor prognosis and rare cancers; ### 68. calls for a more sustainable environment including financial support for conducting research into the repurposing of medicines for cancer treatment , especially performed by third parties with no commercial intent and for the creation of an additional project that uses high-performance computing to rapidly test existing molecules and new drug combinations , starting with high unmet needs , treatment for cancers with a poor prognosis and rare cancers;


### 69. supports the development of clinical trials on the use of new cancer drugs in adults and children; ### 69. supports the development of clinical trials across the eu , for the invention of improved forms of treatment and care for patients , including children and older patients;


### 69. supports the development of clinical trials on the use of new cancer drugs in adults and children; ### 69. supports the development of clinical trials on the use across europe of new cancer drugs in adults and children;


### 69. supports the development of clinical trials on the use of new cancer drugs in adults and children; ### 69. supports the development of clinical trials across europe on the use of new cancer drugs in adults and children;


### 70. welcomes the commission’s intention to adopt a legislative proposal to establish a health emergency preparedness and response authority (hera) in order to anticipate , incentivise , co-develop and facilitate rapid , equal and sustainable access to cancer innovations for cancer patients; calls for a large consortium of public authorities , private companies and ngos , including patient associations , to work together to guarantee the accessibility and affordability of cancer treatment options requiring complex technologies , for instance , cellular therapy (car t cells) , adoptive immunotherapy through the use of tumour genome extracts (messenger rna) and nanotechnologies; ### 70. welcomes the commission’s intention to adopt a legislative proposal to establish a health emergency preparedness and response authority(hera) in order to anticipate , incentivise , co-develop and facilitate rapid , equal and sustainable access to cancer innovations for cancer patients; calls for a large consortium of public authorities , private companies and ngos , including patient associations and academia , to work together to guarantee the accessibility and affordability of cancer treatment options requiring complex technologies , for instance , cellular therapy (car t cells) , adoptive immunotherapy through the use of tumour genome extracts (messenger rna) and nanotechnologies; stresses that , to facilitate wider utilisation of the innovative therapies , the eu and member states must not only do their best to finance currently available therapies but also support the development of more cost- efficient modalities; welcomes , in this regard , the efforts of the świętokrzyskie cancer centre (hcc) in poland in developing car t therapy , which is 6 times less expensive than current options; believes that lowering the costs of the most innovative and effective therapies will increase their wider availability for the benefit of patients in the eu and beyond; calls for securing equal access to innovative therapies , both in the densely populated urban regions and smaller , rural or remote areas;


### 70. welcomes the commission’s intention to adopt a legislative proposal to establish a health emergency preparedness and response authority (hera) in order to anticipate , incentivise , co-develop and facilitate rapid , equal and sustainable access to cancer innovations for cancer patients; calls for a large consortium of public authorities , private companies and ngos , including patient associations , to work together to guarantee the accessibility and affordability of cancer treatment options requiring complex technologies , for instance , cellular therapy (car t cells) , adoptive immunotherapy through the use of tumour genome extracts (messenger rna) and nanotechnologies; ### 70. welcomes the commission’s intention to adopt a legislative proposal to establish a health emergency preparedness and response authority (hera) in order to anticipate , incentivise , co-develop and facilitate rapid , equal and sustainable access to cancer innovations for cancer patients; calls for a large consortium of public authorities , private companies and ngos , including patient associations , to work together to guarantee the accessibility and affordability of cancer treatment options requiring complex technologies , for instance , cellular therapy (car t cells) , adoptive immunotherapy through the use of tumour genome extracts (messenger rna) and nanotechnologies; considers that hera should closely collaborate with public and private entities to plan , coordinate and build an ecosystem of private and public capabilities which can provide suitable emergency frameworks for eu access to key raw materials in case of global supply shocks;


### 70. welcomes the commission’s intention to adopt a legislative proposal to establish a health emergency preparedness and response authority (hera) in order to anticipate , incentivise , co-develop and facilitate rapid , equal and sustainable access to cancer innovations for cancer patients; calls for a large consortium of public authorities , private companies and ngos , including patient associations , to work together to guarantee the accessibility and affordability of cancer treatment options requiring complex technologies , for instance , cellular therapy (car t cells) , adoptive immunotherapy through the use of tumour genome extracts (messenger rna) and nanotechnologies; ### 70. welcomes the commission’s intention to adopt a legislative proposal to establish a health emergency preparedness and response authority (hera) in order to anticipate , incentivise , co-develop and facilitate rapid , equal and sustainable access to cancer innovations for cancer patients; calls for a large consortium of public authorities , private companies and ngos , academia , parent , including patient and survivor associations , to work together to guarantee the accessibility and affordability of cancer treatment options requiring complex technologies , for instance , cellular therapy (car t cells) , adoptive immunotherapy through the use of tumour genome extracts (messenger rna) and nanotechnologies;


### iii.c . equal access to cancer care: towards a better response to the impact of health crises on cancer patients ### iii.c . equal access to integrated , multidisciplinary and quality cancer care: towards a better response to the impact of health crises on cancer patients


### 71. underlines that the covid-19 crisis has had , and is still having , a significant impact on cancer patients’ survival and quality of life at all stages of the disease , due to delays in screening , referral and surgical procedures , treatment postponement , shortages in the supply of medicines and other medical supplies , specialised workforce shortages and reduced communication with health professionals; ### 71. underlines that the covid-19 crisis has had , and is still having , a significant impact on cancer patients’ survival and quality of life at all stages of the disease , due to delays in screening , referral and surgical procedures , treatment postponement , shortages in the supply of medicines and other medical supplies , specialised workforce shortages and reduced communication with health professionals; highlights evidence suggesting that clinicians across europe saw 1.5 million fewer cancer patients in the first year of the pandemic , an estimated 100 million cancer screening tests were not performed in europe as a result of the pandemic , and consequently , 1 million citizens in the eu may presently be undiagnosed with cancer as a consequence of the covid-19 pandemic;


### 72. considers that the covid-19 pandemic was a real stress test for the eu’s health systems; underlines that the main lesson learned should be the need to build an emergency strategy to allow member states to react accordingly in times of any future health crises; stresses that specific measures under this emergency strategy should be aimed at the protection of vulnerable groups , including cancer patients; ### 72. considers that the covid-19 pandemic was a real stress test for the eu’s health systems; underlines that the main lesson learned should be the need to build an emergency strategy to allow member states to react accordingly in times of any future health crises; stresses the need to coordinate crisis strategies at european level; stresses that specific measures under this emergency strategy should be aimed at the protection of vulnerable groups , including cancer patients; calls for the creation of structures that can strengthen cooperation on health policy at eu level , including through the creation of a committee or sub-committee on health in the european parliament;


### 73. notes with concern that the covid-19 pandemic has exacerbated pre-existing health workforce shortages; acknowledges the urgency of ensuring a sufficient number of specialised health professionals in cancer care; reiterates that specific measures under the emergency strategy should be aimed at addressing workforce shortages through the recruitment of health professionals; ### 73. notes with concern that the covid-19 pandemic has exacerbated pre-existing health workforce shortages; acknowledges the urgency of ensuring a sufficient number of specialised health professionals in cancer care; reiterates that specific measures under the emergency strategy should be aimed at addressing workforce shortages through the recruitment of health professionals; recognises that the pandemic has exacerbated the crucial role of informal carers , who provide most of the daily care for cancer patients and who face a clear lack of support (may it be in terms of social rights , training , psychological help , information , recognition); calls on the commission and the members states to create online training platforms as well as therapeutic care programmes granting qualifications and recognising their competences;


### 73. notes with concern that the covid-19 pandemic has exacerbated pre-existing health workforce shortages; acknowledges the urgency of ensuring a sufficient number of specialised health professionals in cancer care; reiterates that specific measures under the emergency strategy should be aimed at addressing workforce shortages through the recruitment of health professionals; ### 73. notes with concern that the covid-19 pandemic has exacerbated pre-existing health workforce shortages; acknowledges the urgency of ensuring a sufficient number of specialised health professionals in cancer care; reiterates that specific measures under the emergency strategy should be aimed at addressing workforce shortages through the recruitment of health professionals; stresses the need for work on a skill mix in order to optimise the response to staffing needs in the health sector; supports the exchange of good practices between member states in this regard;


### 73. notes with concern that the covid-19 pandemic has exacerbated pre-existing health workforce shortages; acknowledges the urgency of ensuring a sufficient number of specialised health professionals in cancer care; reiterates that specific measures under the emergency strategy should be aimed at addressing workforce shortages through the recruitment of health professionals; ### 73. notes with concern that the covid-19 pandemic has exacerbated pre-existing health workforce shortages; acknowledges the urgency of ensuring a sufficient number of specialised health professionals in cancer care; reiterates that specific measures under the emergency strategy should be aimed at addressing workforce shortages through the recruitment of health professionals; underlines the need to work on the so called skill-mix in order to optimise the response on the workforce shortages in healthcare; supports the exchange of best practices between member states in that area;


### 73. notes with concern that the covid-19 pandemic has exacerbated pre-existing health workforce shortages; acknowledges the urgency of ensuring a sufficient number of specialised health professionals in cancer care; reiterates that specific measures under the emergency strategy should be aimed at addressing workforce shortages through the recruitment of health professionals; ### 73. notes with concern that the covid-19 pandemic has exacerbated pre-existing health workforce shortages; acknowledges the urgency of ensuring a sufficient number of specialised health professionals in cancer care; reiterates that specific measures under the emergency strategy should be aimed at addressing workforce shortages through the recruitment of health professionals in both primary and specialised care;


### 74. advocates the development of a digital health system to monitor symptoms and ensure cancer treatment and care at home; calls for permanent access to medical consultations and psychosocial services to be guaranteed through the use of telemedicine or in health threat-free environments in hospitals; ### 74. advocates the development of a digital health system to monitor symptoms and ensure cancer treatment and care at home; encourages the creation of a secure digital communication channel enabling health professionals to monitor patients’ symptoms remotely; calls for permanent access to medical and nutrition consultations and psychosocial services to be guaranteed through the use of telemedicine or in health threat-free environments in hospitals; calls for cross-sector and cross-country collaboration and knowledge sharing that will be crucial for further enhancing the quality of cancer care in the eu;


### 74. advocates the development of a digital health system to monitor symptoms and ensure cancer treatment and care at home; calls for permanent access to medical consultations and psychosocial services to be guaranteed through the use of telemedicine or in health threat-free environments in hospitals; ### 74. advocates the development of a digital health system to monitor symptoms and ensure cancer treatment and care at home; calls for permanent access to medical consultations and psychosocial services , as well as contact between patient and doctor and between the attending doctor and the patient's family , to be guaranteed through the use of telemedicine or in health threat-free environments in hospitals;


### 75. asks for enhanced communication between health professionals , patients and public authorities regarding the effectiveness and safety of health interventions , in particular cancer screening , diagnosis and treatment , and for increased awareness campaigns in times of crises; ### 75. asks for enhanced communication between health professionals , patients and public authorities regarding the effectiveness and safety of health interventions , in particular cancer screening , diagnosis and treatment , and for increased awareness campaigns in times of crises , as well as information on how to eliminate or limit harm caused by certain behaviours , including choosing less harmful alternative products if other options fail;


### 75. asks for enhanced communication between health professionals , patients and public authorities regarding the effectiveness and safety of health interventions , in particular cancer screening , diagnosis and treatment , and for increased awareness campaigns in times of crises; ### 75. asks for enhanced communication between health professionals , parents , patients , survivors and public authorities regarding the effectiveness and safety of health interventions , in particular cancer screening , diagnosis and treatment , and for increased awareness campaigns in times of crises;


### 76. calls on the commission and the member states to adopt european prevention and management plans to address cancer drug shortages in times of health crises; ### 76. calls on the commission and the member states to adopt european prevention and management plans as part of a coherent and holistic contingency strategy to prevent and address shortages of medicines , devices , products and staff in times of health crises;


### 78. emphasises the importance of specific eu recommendations to improve the quality of life of patients , including via supportive care (pain relief , psychological services , adapted physical activity , nutritional support , social assistance , access to reproductive health and restoration of aesthetic integrity); asks member states for recognition of sequelae (physical or mental disabilities) , as well as social discrimination; ### 78. emphasises the importance of specific eu recommendations to improve the quality of life of patients , including via comprehensive supportive care from a bio-psycho-social perspective (pain relief , psychological services , adapted physical activity , scientific evidence-based complementary therapies , nutritional support , social assistance , access to reproductive health and restoration of aesthetic integrity) and integrated into cancer care from diagnosis and throughout the disease process; asks member states for recognition of sequelae (physical or mental disabilities) , as well as social discrimination; recognizes the importance of palliative care as special care for people with life threatening illness and their families , relieving pain and physical , psychosocial and spiritual suffering , while benefitting health systems; highlights that nccps should offer palliative care and a pain management plan for everyone who needs it , for the entire disease trajectory from the beginning and alongside the disease , for adults and also for children; urges the eu to work with member states to address barriers for palliative care , to provide palliative care through primary health care centres as well as at home , and promote palliative care education for all health professionals;


### 78. emphasises the importance of specific eu recommendations to improve the quality of life of patients , including via supportive care (pain relief , psychological services , adapted physical activity , nutritional support , social assistance , access to reproductive health and restoration of aesthetic integrity); asks member states for recognition of sequelae (physical or mental disabilities) , as well as social discrimination; ### 78. recognises that cancer is a financially burdensome disease , even beyond cancer treatments; emphasises the importance of specific eu recommendations to improve the quality of life of patients , including via supportive care (pain relief , psychological services , adapted physical activity , complementary therapies , nutritional support , social assistance encompassing all day-to-day tasks such as household help or child care , access to reproductive health and restoration of aesthetic integrity); recognizes that these types of supportive care are often only developed by private health insurances; asks member states for recognition of sequelae (physical or mental disabilities) , as well as social discrimination; asks the commission to propose guidelines for member states to address the importance of establishing comprehensive coverage systems that guarantee these needs;


### 78. emphasises the importance of specific eu recommendations to improve the quality of life of patients , including via supportive care (pain relief , psychological services , adapted physical activity , nutritional support , social assistance , access to reproductive health and restoration of aesthetic integrity); asks member states for recognition of sequelae (physical or mental disabilities) , as well as social discrimination; ### 78. emphasises the importance of specific eu recommendations to improve the quality of life of patients , including via supportive care (pain relief , psychological services , adapted physical activity , nutritional support , social assistance , access to reproductive health and restoration of aesthetic integrity) , and access to specialised supportive centres; asks member states for recognition of sequelae (physical or mental disabilities) , as well as social discrimination; calls on the commission to set up a platform for the exchange of best practice in palliative care and support research in palliative care; calls on member states to include the aspect of pain management for patients in treatment and survivors;


### 79. encourages member states to take into account the frequent exhaustion of the families and relatives of cancer patients and to provide them with psychological assistance and rest periods in the workplace; ### 79. encourages member states to take into account the frequent exhaustion of the families and relatives of cancer patients and to provide them with psychological assistance and increased flexibility in their working time , or to adapt their working time to the care needs of the patient;


### 79. encourages member states to take into account the frequent exhaustion of the families and relatives of cancer patients and to provide them with psychological assistance and rest periods in the workplace; ### 79. encourages member states to take into account the frequent exhaustion of the families and relatives of cancer patients and to provide them with psychological and socio-economic assistance , especially for the most vulnerable ones , and rest periods in the workplace , along all the illness , as well as bereavement support;


### 80. recalls that patient empowerment is crucial for the european cancer strategy and that patient-centeredness and participatory decision-making must be at the heart of treatment and care development processes; encourages the therapeutic education of caregivers and patients and their empowerment in the care programmes; ### 80. recalls that patient empowerment is crucial for the european cancer strategy and that patient-centeredness and participatory decision-making must be at the heart of treatment and care development processes; encourages the therapeutic education of caregivers and patients and their empowerment in the care programmes; encourages the development of the role of treatment coordinator in each member state , which could serve as a contact point to help patients make optimal use of the services provided by the health system;


### 80. recalls that patient empowerment is crucial for the european cancer strategy and that patient-centeredness and participatory decision-making must be at the heart of treatment and care development processes; encourages the therapeutic education of caregivers and patients and their empowerment in the care programmes; ### 80. recalls that patient empowerment is crucial for the european cancer strategy and that patient-centeredness and participatory decision-making must be at the heart of treatment and care development processes; encourages the therapeutic education of caregivers and patients and their empowerment in the care programmes; recommends that eu4health programme supports initiatives and actions to empower cancer patients.


### 81. acknowledges the positive role of patients’ associations in relation to patient advocacy and accompaniment; calls on the commission and the member states to take into account their requests and recommendations when formulating cancer-related policies and legislation and to provide them with public support in order to guarantee their independence from private funding; ### 81. acknowledges the central role of patients’ and carers’ associations in relation to patient advocacy and accompaniment , dissemination of health literacy , and awareness and ongoing support both at eu and national level; calls on the commission and the member states to include them in upcoming financial programs and specific projects and to guarantee operational funding , take into account their requests and recommendations when formulating cancer-related policies and legislation and to provide them with public support in form of both operating grants and project related grants in order to guarantee their independence from private funding;


### 82. calls on the member states to improve the reintegration of cancer survivors into the labour market and to facilitate the return to school of paediatric cancer survivors; advocates specific eu recommendations for measures for cancer survivors to prevent the recurrence of primary cancer and the development of new cancers and for their rehabilitation; ### 82. calls on the member states to improve the reintegration of cancer survivors into the labour market and to facilitate the return to school of paediatric cancer survivors; advocates specific eu recommendations for measures for cancer survivors to prevent the recurrence of primary cancer and the development of new cancers and for their rehabilitation; calls on the member states to support the reintegration of people with cancer into the labour market and to facilitate the balancing of work with treatment and rehabilitation needs; calls for support for employers who employ people who have had or who currently have cancer;


### 82. calls on the member states to improve the reintegration of cancer survivors into the labour market and to facilitate the return to school of paediatric cancer survivors; advocates specific eu recommendations for measures for cancer survivors to prevent the recurrence of primary cancer and the development of new cancers and for their rehabilitation; ### 82. calls on the member states to improve the reintegration of cancer survivors into the labour market and to facilitate the return to school of paediatric cancer survivors; advocates specific eu recommendations for measures for cancer survivors to prevent the recurrence of primary cancer and the development of new cancers and for their rehabilitation; calls on the member states to support the re-entry of cancer patients to the labour market and to facilitate the sharing of work and rehabilitation process;


### 82. calls on the member states to improve the reintegration of cancer survivors into the labour market and to facilitate the return to school of paediatric cancer survivors; advocates specific eu recommendations for measures for cancer survivors to prevent the recurrence of primary cancer and the development of new cancers and for their rehabilitation; ### 82. calls on the member states to improve the reintegration of cancer survivors into the labour market and to facilitate the return to school of paediatric cancer survivors; advocates specific eu recommendations for measures for cancer survivors to prevent the recurrence of primary cancer and the development of new cancers and for their rehabilitation; including specific provisions for long-term follow-up care for childhood cancer survivors as they transition into adulthood;


### 82. calls on the member states to improve the reintegration of cancer survivors into the labour market and to facilitate the return to school of paediatric cancer survivors; advocates specific eu recommendations for measures for cancer survivors to prevent the recurrence of primary cancer and the development of new cancers and for their rehabilitation; ### 82. calls on the member states to improve the reintegration of cancer survivors into the labour market and to facilitate the return to school or higher education of paediatric cancer survivors; advocates specific eu recommendations for measures for cancer survivors to prevent the recurrence of primary cancer and the development of new cancers and for their rehabilitation;


### 83. considers that the european agency for health and safety at work should be mandated to play a stronger role in promoting good practices in member states with respect to the integration of cancer patients and survivors into the workplace and their protection from discrimination; looks forward to the new study , announced in europe’s beating cancer plan , on the return to work of cancer survivors , which will map national employment and social protection policies and identify obstacles and the remaining challenges; ### 83. considers that the european agency for health and safety at work should be mandated to play a stronger role in promoting good practices in member states with respect to the integration of cancer patients and survivors into the workplace and their protection from discrimination; looks forward to the new study , announced in europe’s beating cancer plan , on the return to work of cancer survivors , which will map national employment and social protection policies and identify obstacles and the remaining challenges , as well as the direct economic impact that cancer has on patients and their families , especially on those groups that are most vulnerable due to their socio-economic situation;


### a. whereas europe’s beating cancer plan should effectively respond to the call for progress by the families and doctors of the 1.3 million people who die from cancer each year in europe , including 6 000 children , the crucial needs of patients who are currently in need of efficient and innovative treatments , the rightful expectations of more than 12 million cancer survivors facing the difficult return back to a ‘normal life’ , the clear will of future generations to be protected against health threats , and the concern of governments facing a growing economic burden from cancer and its related treatments; ### a. whereas europe’s beating cancer plan should effectively respond to the call for progress by the families and doctors of the 1.3 million people who die from cancer each year in europe , including 6 000 children , the crucial needs of patients who are currently in need of rapid diagnosis , as well as efficient and innovative treatments , the rightful expectations of more than 12 million cancer survivors and their families facing the difficult return back to a ‘normal life’ , the clear will of future generations to be protected against health threats , and the concern of governments facing a growing economic burden from cancer and its related treatments; whereas all union actions in the fight against cancer should aim to increase the five-year survival rate of cancer patients; whereas the early detection rate of cancer should be increased by 25% by 2030 compared to 2020;


### a. whereas europe’s beating cancer plan should effectively respond to the call for progress by the families and doctors of the 1.3 million people who die from cancer each year in europe , including 6 000 children , the crucial needs of patients who are currently in need of efficient and innovative treatments , the rightful expectations of more than 12 million cancer survivors facing the difficult return back to a ‘normal life’ , the clear will of future generations to be protected against health threats , and the concern of governments facing a growing economic burden from cancer and its related treatments; ### a. whereas europe’s beating cancer plan should effectively respond to the call for progress by the families and doctors of the 1.3 million people who die from cancer each year in europe , including 6 000 children , the crucial needs of patients who are currently in need of efficient and innovative treatments for cancer and cancer-related complications and comorbidities , the rightful expectations of more than 12 million cancer survivors facing the difficult return back to a ‘normal life’ , the clear will of future generations to be protected against health threats , and the concern of governments facing a growing economic burden from cancer and its related treatments;


### a. whereas europe’s beating cancer plan should effectively respond to the call for progress by the families and doctors of the 1.3 million people who die from cancer each year in europe , including 6 000 children , the crucial needs of patients who are currently in need of efficient and innovative treatments , the rightful expectations of more than 12 million cancer survivors facing the difficult return back to a ‘normal life’ , the clear will of future generations to be protected against health threats , and the concern of governments facing a growing economic burden from cancer and its related treatments; ### a. whereas europe’s beating cancer plan should effectively respond to the call for progress by the families and healthcare professionals of the 1.3 million people who die from cancer each year in europe , including 6 000 children , the crucial needs of patients who are currently in need of efficient and innovative treatments , the rightful expectations of more than 12 million cancer survivors facing the difficult return back to a ‘normal life’ , the clear will of future generations to be protected against health threats , and the concern of governments facing a growing economic burden from cancer and its related treatments;


### b. whereas europe represents less than 10 % of the world’s population , but accounts for a quarter of all cancer cases , and whereas cancer is the second leading cause of death in europe after cardiovascular diseases; whereas although there has been a slight decrease in mortality rates thanks to screening campaigns and therapeutic innovation , the number of cases diagnosed is nevertheless increasing , notably due to longer life expectancies , which results in ageing populations; whereas almost three quarters of all cancer diagnoses in the eu occur in people aged 60 or above; ### b. whereas europe represents less than 10 % of the world’s population , but accounts for a quarter of all cancer cases , and whereas cancer is the second leading cause of death in europe after cardiovascular diseases; and the first cause of death by disease in children older than one year of age whereas although there has been a slight decrease in mortality rates thanks to screening campaigns and therapeutic innovation , the number of cases diagnosed is nevertheless increasing , notably due to longer life expectancies , which results in ageing populations; whereas almost three quarters of all cancer diagnoses in the eu occur in people aged 60 or above; whereas the specific needs of children and adolescents with cancer require continued attention and support globally;


### b. whereas europe represents less than 10 % of the world’s population , but accounts for a quarter of all cancer cases , and whereas cancer is the second leading cause of death in europe after cardiovascular diseases; whereas although there has been a slight decrease in mortality rates thanks to screening campaigns and therapeutic innovation , the number of cases diagnosed is nevertheless increasing , notably due to longer life expectancies , which results in ageing populations; whereas almost three quarters of all cancer diagnoses in the eu occur in people aged 60 or above; ### b. whereas europe represents less than 10 % of the world’s population , but accounts for a quarter of all cancer cases , and whereas cancer is the second leading cause of death in europe after cardiovascular diseases; whereas although there has been a slight decrease in mortality rates thanks to screening campaigns and therapeutic innovation , the number of cases diagnosed is nevertheless increasing , notably due to longer life expectancies; whereas almost three quarters of all cancer diagnoses in the eu occur in people aged 60 or above;


### c. whereas cancer illustrates social injustice in healthcare , as differences in cancer survival rates across the eu member states exceed 25 %; whereas eu citizens are unequal in terms of prevention , unequally protected against risk factors , unequally educated in terms of healthy behaviours and unequally equipped against misinformation; whereas eu citizens are unequal in terms of timely access to quality care from member state to member state and from region to region in any given country; whereas after recovery or when in remission , eu citizens are unequal in their ability to return to work , to be financially independent and to return to a harmonious familial , social and emotional life; ### c. whereas cancer illustrates social injustice in healthcare , as differences in cancer survival rates across the eu member states exceed 25 %; whereas eu citizens are unequal in terms of prevention , unequally protected against risk factors , unequally educated in terms of healthy behaviours and unequally equipped against misinformation; whereas eu citizens are unequal in terms of timely access to quality care from member state to member state and from region to region in any given country; whereas access to fully multidisciplinary and multi-professional teams varies widely across europe; whereas after recovery or when in remission , eu citizens are unequal in their ability to return to work , to be financially independent and to return to a harmonious familial , social and emotional life;


### c. whereas cancer illustrates social injustice in healthcare , as differences in cancer survival rates across the eu member states exceed 25 %; whereas eu citizens are unequal in terms of prevention , unequally protected against risk factors , unequally educated in terms of healthy behaviours and unequally equipped against misinformation; whereas eu citizens are unequal in terms of timely access to quality care from member state to member state and from region to region in any given country; whereas after recovery or when in remission , eu citizens are unequal in their ability to return to work , to be financially independent and to return to a harmonious familial , social and emotional life; ### c. whereas cancer illustrates social injustice in healthcare , as differences in cancer survival rates across the eu member states exceed 25 %; whereas eu citizens are unequal in terms of prevention , unequally protected against risk factors , unequally educated in terms of healthy behaviours and unequally equipped against misinformation; whereas eu citizens are unequal in terms of timely access to affordable , accessible , and quality medicines , treatment , health technologies and care from member state to member state and from region to region in any given country; whereas after recovery or when in remission , eu citizens are unequal in their ability to return to work , to be financially independent and to return to a harmonious familial , social and emotional life;


### d. whereas specific national or regional cancer policies have been set up in most member states , whose missions and budgets are heterogeneous; ### d. whereas specific national or regional cancer policies have been set up in most member states , whose missions , capacity and budgets are heterogeneous;


### e. whereas the goal of europe’s beating cancer plan should not only be to fight against a crucial public health issue and to help patients live longer and better lives , but should also be to initiate a reduction in health inequalities and inequities and lower the social and economic burden of the disease; whereas the commission should promote a patient-centred and citizens’ rights-based approach by integrating considerations of justice , sustainability , equity , solidarity , innovation and collaboration at the very core of europe’s beating cancer plan; ### e. whereas the goal of europe’s beating cancer plan should not only be to fight against a crucial public health issue and to help patients live longer and better lives , but should also be to initiate a reduction in health inequalities and inequities and lower the social and economic burden of the disease; whereas the commission should promote a patient-centred and citizens’ rights-based approach by integrating considerations of justice , sustainability , equity , solidarity , innovation and collaboration at the very core of europe’s beating cancer plan and by recognising the potential for gaining economies of scale from joint action at european level;


### e. whereas the goal of europe’s beating cancer plan should not only be to fight against a crucial public health issue and to help patients live longer and better lives , but should also be to initiate a reduction in health inequalities and inequities and lower the social and economic burden of the disease; whereas the commission should promote a patient-centred and citizens’ rights-based approach by integrating considerations of justice , sustainability , equity , solidarity , innovation and collaboration at the very core of europe’s beating cancer plan; ### e. whereas the goal of europe’s beating cancer plan should not only be to fight against a crucial public health issue and to help patients live longer and better lives , but should also be to initiate a reduction in health inequalities and inequities and lower the social and economic burden of the disease; whereas the commission should promote a patient-centred and citizens’ rights-based approach by integrating considerations of justice , sustainability , equity , solidarity , innovation and collaboration at the very core of europe’s beating cancer plan; including its 'helping children with cancer initiative';


### f. whereas health literacy includes the acquisition of knowledge and skills , awareness of rights and the confidence to take action to improve personal and community health; whereas actions to promote health literacy under the plan should focus on empowering patients and citizens; whereas all efforts to increase health literacy should take into account people with learning disabilities , as well as ensure that the necessary information is available in common non-eu languages in order to reach migrants and new arrivals; ### f. whereas health literacy includes the acquisition of knowledge and skills , awareness of rights and the confidence to take action to improve personal and community health; whereas actions to promote health literacy under the plan should focus on empowering patients and citizens also by seeking the expertise of , and collaborating with , patient organisations and other ngos which have been working on disseminating and spreading health literacy for years; whereas patient empowerment requires assisting patients understand their rights , including specifically as cancer patients; whereas all efforts to increase health literacy should take into account regional and national , social and economic differences and the needs of people with learning disabilities , as well as ensure that the necessary information is available in common non-eu languages in order to reach migrants and new arrivals; whereas efforts to improve health literacy should also include an onus on assisting citizens to identify misinformation , noting the harmful impacts this can have across all areas of cancer care including prevention , vaccination and treatment;


### f. whereas health literacy includes the acquisition of knowledge and skills , awareness of rights and the confidence to take action to improve personal and community health; whereas actions to promote health literacy under the plan should focus on empowering patients and citizens; whereas all efforts to increase health literacy should take into account people with learning disabilities , as well as ensure that the necessary information is available in common non-eu languages in order to reach migrants and new arrivals; ### f. whereas health literacy includes the acquisition of knowledge and skills , awareness of rights and the confidence to take action to improve personal and community health; whereas actions to promote health literacy under the plan should focus on empowering patients and citizens; whereas all efforts to increase health literacy should take into account people with learning disabilities , as well as ensure that the necessary information is available in common non-eu languages in order to reach migrants and new arrivals and other minority communities;


### f. whereas health literacy includes the acquisition of knowledge and skills , awareness of rights and the confidence to take action to improve personal and community health; whereas actions to promote health literacy under the plan should focus on empowering patients and citizens; whereas all efforts to increase health literacy should take into account people with learning disabilities , as well as ensure that the necessary information is available in common non-eu languages in order to reach migrants and new arrivals; ### f. whereas health literacy includes the acquisition of knowledge and skills , awareness of rights and the confidence to take action to improve personal and community health; whereas actions to promote health literacy under the plan should focus on empowering patients and citizens through state-of-the-art communication tools; whereas all efforts to increase health literacy should take into account people who are experiencing exclusion and who have difficulties in accessing knowledge , as well as ensure that the necessary information is available in common non-eu languages in order to reach migrants and new arrivals;


### g. whereas the plan should be implemented in close association with the recommendations and actions of the international agency for research on cancer (iarc) , the un sdgs for global health , and the recommendations and guidelines of the world health organization (who) , and should acknowledge as a priority the eu’s solidarity and partnership with low- and middle-income countries; ### g. whereas the plan should be implemented in close association with the recommendations and actions of the international agency for research on cancer (iarc) , the un sdgs for global health , and the recommendations and guidelines of the world health organization (who) , including the who global initiative for childhood cancer , and the eu joint actions on cancer , and should acknowledge as a priority the eu’s solidarity and partnership with low- and middle-income countries;


### g. whereas the plan should be implemented in close association with the recommendations and actions of the international agency for research on cancer (iarc) , the un sdgs for global health , and the recommendations and guidelines of the world health organization (who) , and should acknowledge as a priority the eu’s solidarity and partnership with low- and middle-income countries; ### g. whereas the plan should be implemented in close association with the recommendations and actions of the international agency for research on cancer (iarc) , the un sdgs for global health , and the recommendations and guidelines of the world health organization (who) , and should acknowledge as a priority the eu’s solidarity and partnership with low- and middle-income countries; including those in the wider who europe region.


### h. whereas addressing cancer could be used as a model for other non-communicable diseases , and whereas patients with other chronic diseases should therefore also benefit from the achievements of europe’s beating cancer plan; ### h. whereas the lessons learnt from addressing breast cancer in the eu could serve as a blueprint for other cancer areas; whereas addressing cancer could be used as a model for other non-communicable diseases , and whereas patients with other chronic diseases should therefore also benefit from the achievements of europe’s beating cancer plan;


### j. whereas a comprehensive , multidisciplinary and coordinated approach to addressing social , individual , environmental and commercial health determinants is needed at regional , national and european level in order to support actions targeting all aspects of cancer (prevention , detection , treatment , palliative care and reintegration) through the effective mobilisation of key tools such as research and knowledge sharing; whereas new technologies and artificial intelligence have high potential for improvements in the field of cancer research; ### j. whereas a comprehensive , multidisciplinary and coordinated approach to addressing social , individual , environmental and commercial health determinants is needed at regional , national and european level in order to support actions targeting all aspects of cancer (prevention , detection , treatment , palliative care and reintegration) through the effective mobilisation of key tools such as research and knowledge sharing; whereas patient-centric approaches to treatment such as integrative oncology , based on scientific evidences , have shown to improve the quality of life and overall survivorship of patients; whereas new technologies and artificial intelligence have high potential for improvements in the field of cancer research;


### j. whereas a comprehensive , multidisciplinary and coordinated approach to addressing social , individual , environmental and commercial health determinants is needed at regional , national and european level in order to support actions targeting all aspects of cancer (prevention , detection , treatment , palliative care and reintegration) through the effective mobilisation of key tools such as research and knowledge sharing; whereas new technologies and artificial intelligence have high potential for improvements in the field of cancer research; ### j. whereas a comprehensive , multidisciplinary and coordinated approach to addressing social , individual , environmental and commercial health determinants is needed at regional , national and european level in order to support actions targeting all aspects of cancer (prevention , detection , treatment , palliative care and reintegration) through the effective mobilisation of key tools such as research and knowledge sharing; whereas patient-centric approaches to treatment as found in integrative oncology can improve the quality of life; whereas new technologies and artificial intelligence have high potential for improvements in the field of cancer research;


### j. whereas a comprehensive , multidisciplinary and coordinated approach to addressing social , individual , environmental and commercial health determinants is needed at regional , national and european level in order to support actions targeting all aspects of cancer (prevention , detection , treatment , palliative care and reintegration) through the effective mobilisation of key tools such as research and knowledge sharing; whereas new technologies and artificial intelligence have high potential for improvements in the field of cancer research; ### j. whereas a comprehensive , multidisciplinary and coordinated approach to addressing social , individual , environmental and commercial health determinants is needed at regional , national and european level in order to support actions targeting all aspects of cancer (prevention , detection , treatment , palliative care follow-up care for survivors and reintegration) through the effective mobilisation of key tools such as research and knowledge sharing; whereas new technologies and artificial intelligence have high potential for improvements in the field of cancer research;


### j. whereas a comprehensive , multidisciplinary and coordinated approach to addressing social , individual , environmental and commercial health determinants is needed at regional , national and european level in order to support actions targeting all aspects of cancer (prevention , detection , treatment , palliative care and reintegration) through the effective mobilisation of key tools such as research and knowledge sharing; whereas new technologies and artificial intelligence have high potential for improvements in the field of cancer research; ### j. whereas a comprehensive , multidisciplinary and coordinated approach to addressing social , individual , environmental and commercial health determinants is needed at regional , national and european level in order to support actions targeting all aspects of cancer (prevention , detection , treatment , palliative care and reintegration) through the effective mobilisation of key tools such as research and knowledge sharing; whereas new technologies and artificial intelligence have high potential for improvements in the field of cancer research and in the treatment process;


### j. whereas a comprehensive , multidisciplinary and coordinated approach to addressing social , individual , environmental and commercial health determinants is needed at regional , national and european level in order to support actions targeting all aspects of cancer (prevention , detection , treatment , palliative care and reintegration) through the effective mobilisation of key tools such as research and knowledge sharing; whereas new technologies and artificial intelligence have high potential for improvements in the field of cancer research; ### j. whereas a comprehensive , multidisciplinary and coordinated approach to addressing social , individual , environmental , work related and commercial health determinants is needed at regional , national and european level in order to support actions targeting all aspects of cancer (prevention , detection , treatment , palliative care and reintegration) through the effective mobilisation of key tools such as research and knowledge sharing; whereas new technologies and artificial intelligence have high potential for improvements in the field of cancer research;


### m. whereas europe’s beating cancer plan could therefore represent the first step towards a real european health union; ### m. whereas europe’s beating cancer plan could therefore represent an important step towards a real european health union and a public demonstration to citizens of the success that eu health cooperation can achieve.


### m. whereas europe’s beating cancer plan could therefore represent the first step towards a real european health union; ### m. whereas europe’s beating cancer plan could therefore represent an important step towards a real european health union;


### 1. strongly believes that preventive actions against cancer should be implemented in all european policies and funding programmes; ### 1. strongly believes that raising public awareness and preventive actions against cancer should be implemented in all european policies and funding programmes;


### 1. strongly believes that preventive actions against cancer should be implemented in all european policies and funding programmes; ### 1. strongly believes that comprehensive preventive actions against cancer should be implemented in all european policies and funding programmes;


### 2. calls on the commission and member states to design and implement effective prevention measures at national and eu level , based on best practices , independent expertise and guidance; ### 2. calls on the commission and member states to design and implement effective prevention measures aiming at eliminating or reducing harm at national and eu level , based on best practices , independent scientific expertise and guidance;


### 2. calls on the commission and member states to design and implement effective prevention measures at national and eu level , based on best practices , independent expertise and guidance; ### 2. calls on the commission and member states to design and implement effective prevention measures aimed at eliminating or reducing damage at national and eu level , based on best practices , independent expertise and guidance;


### 2. calls on the commission and member states to design and implement effective prevention measures at national and eu level , based on best practices , independent expertise and guidance; ### 2. calls on the commission and member states to design and implement effective prevention measures at national and eu level , based on best practices , data-based expertise and clinical guidance;


### 3. acknowledges that more than 40 % of all cancers are preventable through coordinated actions on social , individual , environmental and commercial health determinants; ### 3. acknowledges that more than 40 % of all adult cancers are preventable through coordinated actions on social , individual , environmental and commercial health determinants; stresses the need for focus on genetic predisposition for early detection in childhood cancers as a disease that develops early in life over a short time period;


### 3. acknowledges that more than 40 % of all cancers are preventable through coordinated actions on social , individual , environmental and commercial health determinants; ### 3. acknowledges that more than 40 % of all cancers are preventable through coordinated actions on social , individual , environmental , work-related and commercial health determinants;


### 4. supports the aim of the horizon europe cancer mission to avert more than 3 million additional premature deaths over the 2021-2030 period , by accelerating progress in cancer prevention and control programmes and creating more equal access to these programmes; ### 4. supports the aim of the horizon europe cancer mission to avert more than 3 million additional premature deaths over the 2021-2030 period , by accelerating progress in cancer prevention and control programmes and creating equal access to these programmes;


### 5. deplores the significant health inequalities in the eu as regards cancer prevention; insists on the need to pay special attention to vulnerable and marginalised populations in order to ensure their access to cancer prevention services; ### 5. deplores the significant health inequalities in the eu as regards cancer prevention; insists on the need to pay special attention to vulnerable and marginalised populations in order to ensure their access to cancer prevention services; these cancer prevention services must also include access to the appropriate tools and services to prevent transmission of carcinogenic viruses , access to human papilloma virus and hepatitis b virus (hbv) vaccination , access to testing and state of the art treatment and care for these viral infections , including regular monitoring and surveillance post infection;


### 5. deplores the significant health inequalities in the eu as regards cancer prevention; insists on the need to pay special attention to vulnerable and marginalised populations in order to ensure their access to cancer prevention services; ### 5. deplores the significant health inequalities in the eu as regards cancer prevention and screening; insists on the need to pay special attention to vulnerable and marginalised populations in order to ensure their access to cancer prevention services; and involve them in organised screening programmes;


### 5. deplores the significant health inequalities in the eu as regards cancer prevention; insists on the need to pay special attention to vulnerable and marginalised populations in order to ensure their access to cancer prevention services; ### 5. deplores the significant health inequalities in the eu as regards cancer prevention; insists on the need to pay special attention to vulnerable and marginalised populations in order to ensure their access to cancer prevention services; such as smoking cessation services , obesity treatment and hpv vaccination;


### 5. deplores the significant health inequalities in the eu as regards cancer prevention; insists on the need to pay special attention to vulnerable and marginalised populations in order to ensure their access to cancer prevention services; ### 5. deplores the significant health inequalities in the eu as regards cancer prevention; insists on the need to identify , as well as to pay special attention to , vulnerable and marginalised populations in order to ensure their access to cancer prevention services;


### 7. strongly supports the goal of a ‘tobacco-free generation’ , as set out in europe’s beating cancer plan , where less than 5 % of the population uses tobacco by 2040 , compared to around 25 % today; ### 7. strongly supports the goal of a ‘tobacco-free generation’ , as set out in europe’s beating cancer plan , where less than 5 % of the population uses tobacco by 2040 , compared to around 25 % today; calls on the commission to fund programmes that promote smoking cessation; calls on the commission to back cooperation between member states in exchanging the best and most effective practices for reducing smoking;


### 7. strongly supports the goal of a ‘tobacco-free generation’ , as set out in europe’s beating cancer plan , where less than 5 % of the population uses tobacco by 2040 , compared to around 25 % today; ### 7. strongly supports the goal of a ‘tobacco-free generation’ , as set out in europe’s beating cancer plan , where less than 5 % of the population uses tobacco by 2040 , compared to around 25 % today; urges that progress towards interim goals towards this target be reported within the cancer inequalities registry in order to best direct efforts to achieve the overall target;


### an increase in minimum excise duties for all tobacco products , which could result in a reduction in tobacco use , notably among young people; ### an increase in minimum excise duties for all tobacco products , while taking into account differences in rules between member states , which could result in a reduction in tobacco use , notably among young people;


### a ban on flavourings in all tobacco products to reduce the appeal of these products to non-smokers and young people; ### a ban on flavourings in all tobacco products , which should not apply to electronic cigarettes , to reduce the appeal of these products to non-smokers and young people;


### a ban on flavourings in all tobacco products to reduce the appeal of these products to non-smokers and young people; ### stricter enforcement of a ban on flavourings in all tobacco products for smoking to reduce the appeal of these products to non-smokers and young people;


### a ban on flavourings in all tobacco products to reduce the appeal of these products to non-smokers and young people; ### a ban on flavourings in all tobacco products to reduce the appeal of these products to smokers , non-smokers and young people;


### an authorisation for member states to introduce a ban on plastic cigarette filters on health and environmental grounds; ### an evaluation of directive (eu) 2019/904 of the european parliament and of the council of 5 june 2019 on the reduction of the impact of certain plastic products on the environment by member states with regards to a discussion on cigarette filters , their environmental impact and the potential health consequences of removing them;


### an authorisation for member states to introduce a ban on plastic cigarette filters on health and environmental grounds; ### a re-iteration of the call to member states to implement the obligations under the single use plastics directive (directive (eu) 2019/904) as regards filters in tobacco products containing plastics;


### an authorisation for member states to introduce a ban on plastic cigarette filters on health and environmental grounds; ### an authorisation for member states to introduce a ban on unfiltered cigarettes on health grounds , and present regulation aiming towards a gradual elimination of plastic in the filters due to environmental concerns;


### the continuation of evaluations of the health risks related to electronic cigarettes and the establishment of a list of substances contained and emitted by these products at european level , based on the model published by the french agency for health security; ### the continuation of evaluations of the relative health risks related to electronic cigarettes , comparing them to other tobacco products and also including the harm reduction arguments into the evaluation , and the establishment of a list of substances contained and emitted by these products at european level , based on the model published by the french agency for health security;


### the continuation of evaluations of the health risks related to electronic cigarettes and the establishment of a list of substances contained and emitted by these products at european level , based on the model published by the french agency for health security; ### the continuation of scientific evaluations of the health risks related to electronic cigarettes and novel tobacco products and other emerging products , including the assessment of relative risk of using these products compared to continued smoking of cigarettes , and the establishment of a list of substances contained and emitted by these products at european level , based on the model published by the french agency for health security;


### the continuation of evaluations of the health risks related to electronic cigarettes and the establishment of a list of substances contained and emitted by these products at european level , based on the model published by the french agency for health security; ### the continuation of evaluations of the most recent scientific and technical information on electronic cigarettes and heated tobacco products , and the establishment of a list of substances contained and emitted by these products at european level , based on the model published by the french agency for health security; call on the commission to support actions whose aim is to discourage youth to take up smoking tobacco;


### the continuation of evaluations of the health risks related to electronic cigarettes and the establishment of a list of substances contained and emitted by these products at european level , based on the model published by the french agency for health security; ### the continuation of evaluations of the health risks related to electronic cigarettes and the establishment of a list of substances contained and emitted by these products at european level , based on the model published by the french agency for health security; calls on the commission to support measures aimed at discouraging young people from taking up smoking;


### 9. calls for the rapid implementation of the who framework convention on tobacco control , paying specific attention to the protection of public health policies from the vested interests of the tobacco industry. ### 9. calls for the rapid and complete implementation of the who framework convention on tobacco control , paying specific attention to the protection of public health policies from the vested interests of the tobacco industry;


### 10. supports the commission’s proposal to update the council recommendation of 30 november 2009 on smoke-free environments12 to extend its coverage to emerging products , such as e-cigarettes and heated tobacco products , and to extend smoke-free environments , including outdoor spaces; ### 10. supports the commission’s proposal to update the council recommendation of 30 november 2009 on smoke-free environments12;


### 11. recalls that ethanol and acetaldehyde in alcoholic beverages are classified as carcinogenic to humans by the iarc , and that in europe an estimated 10 % of all cancer cases in men and 3 % of all cancer cases in women are attributable to alcohol consumption; ### 11. recalls that ethanol and acetaldehyde in alcoholic beverages are classified as carcinogenic to humans by the iarc , and that in europe an estimated 10 % of all cancer cases in men and 3 % of all cancer cases in women are attributable to alcohol consumption; notes that alcohol consumption is a key factor in developing over 60 diseases and conditions , including seven types of cancer: mouth , upper throat , larynx , oesophagus , breast , liver , and colorectal cancer;


### 11. recalls that ethanol and acetaldehyde in alcoholic beverages are classified as carcinogenic to humans by the iarc , and that in europe an estimated 10 % of all cancer cases in men and 3 % of all cancer cases in women are attributable to alcohol consumption; ### 11. recalls that ethanol and acetaldehyde in alcoholic beverages are classified as carcinogenic to humans by the iarc , and that in europe an estimated 10 % of all cancer cases in men and 3 % of all cancer cases in women are attributable to alcohol consumption over and beyond the recommended quantities;


### 11. recalls that ethanol and acetaldehyde in alcoholic beverages are classified as carcinogenic to humans by the iarc , and that in europe an estimated 10 % of all cancer cases in men and 3 % of all cancer cases in women are attributable to alcohol consumption; ### 11. recalls that acetaldehyde from ethanol metabolism is classified as carcinogenic to humans by the iarc , and that in europe an estimated 4.3 % of all cancer cases are attributable to harmful alcohol consumption;


### 11. recalls that ethanol and acetaldehyde in alcoholic beverages are classified as carcinogenic to humans by the iarc , and that in europe an estimated 10 % of all cancer cases in men and 3 % of all cancer cases in women are attributable to alcohol consumption; ### 11. recalls that acetaldehyde from ethanol metabolism in all types of alcoholic beverages is classified as carcinogenic to humans by the iarc , and that in europe an estimated 4.3 % of all cancer cases are attributable to harmful alcohol consumption;


### 84. supports the upcoming roll-out of a cancer survivor smart card , as announced in europe’s beating cancer plan , to all european cancer survivors , especially survivors of childhood and adolescent cancers , which will summarise their clinical history , including patients’ own experience , and facilitate and monitor follow-up care; ### 84. supports the upcoming roll-out of a cancer survivor smart card , as announced in europe’s beating cancer plan , to all european cancer survivors , especially survivors of childhood and adolescent cancers for whom the survivorship passport model exists as a basis , which will summarise their clinical history , including patients’ own experience , and facilitate and monitor follow-up care;


### 85. considers that insurers and banks should not take into account the medical history of people who have been affected by cancer; calls for national legislation to ensure that cancer survivors are not discriminated against compared to other consumers; notes the commission’s intention to engage with businesses to develop a code of conduct to ensure that developments in cancer treatments and their improved effectiveness are reflected in the business practices of financial service providers; supports , in parallel , the promotion of advances made in france , belgium , luxembourg and the netherlands , where cancer survivors enjoy the ‘right to be forgotten’; requests that by 2025 , at the latest , all member states should guarantee the right to be forgotten to all european patients ten years after the end of their treatment , and five years after the end of treatment for patients whose diagnosis was made before the age of 18; calls for the introduction of common standards for the right to be forgotten under the relevant provisions on consumer protection policy of the treaty on the functioning of the european union , in order to remedy the fragmented national practices in the area of creditworthiness assessment and ensure equal access to credit for cancer survivors; ### 85. considers that insurers and banks should not take into account the medical history of people who have been affected by cancer; calls for embedding the right to be forgotten for cancer-survivors in eu legislation to prevent discrimination and improve the access of cancer survivors to financial services; notes the commission’s intention to engage with businesses to develop a code of conduct to ensure that developments in cancer treatments and their improved effectiveness are reflected in the business practices of financial service providers; supports , in parallel , the promotion of advances made in france , belgium , luxembourg and the netherlands , where cancer survivors enjoy the ‘right to be forgotten’; requests that by 2025 , at the latest , all member states should guarantee the right to be forgotten to all european patients ten years after the end of their treatment , and five years after the end of treatment for patients whose diagnosis was made before the age of 18; calls for the introduction of common standards for the right to be forgotten under the relevant provisions on consumer protection policy of the treaty on the functioning of the european union , in order to remedy the fragmented national practices in the area of creditworthiness assessment and ensure equal access to credit for cancer survivors;


### 85. considers that insurers and banks should not take into account the medical history of people who have been affected by cancer; calls for national legislation to ensure that cancer survivors are not discriminated against compared to other consumers; notes the commission’s intention to engage with businesses to develop a code of conduct to ensure that developments in cancer treatments and their improved effectiveness are reflected in the business practices of financial service providers; supports , in parallel , the promotion of advances made in france , belgium , luxembourg and the netherlands , where cancer survivors enjoy the ‘right to be forgotten’; requests that by 2025 , at the latest , all member states should guarantee the right to be forgotten to all european patients ten years after the end of their treatment , and five years after the end of treatment for patients whose diagnosis was made before the age of 18; calls for the introduction of common standards for the right to be forgotten under the relevant provisions on consumer protection policy of the treaty on the functioning of the european union , in order to remedy the fragmented national practices in the area of creditworthiness assessment and ensure equal access to credit for cancer survivors; ### 85. considers that insurers and banks should not take into account the medical history of people who have been affected by cancer; calls for national legislation to ensure that cancer survivors are not discriminated against compared to other consumers; notes the commission’s intention to engage with businesses to develop a code of conduct to ensure that developments in cancer treatments and their improved effectiveness are reflected in the business practices of financial service providers; supports , in parallel , the promotion of advances made in france , belgium , luxembourg and the netherlands , where cancer survivors enjoy the ‘right to be forgotten’; requests that by 2025 , at the latest , all member states should guarantee the right to be forgotten to all european patients ten years after the end of their treatment , and up to five years after the end of treatment for patients whose diagnosis was made before the age of 18; calls for the introduction of common standards for the right to be forgotten under the relevant provisions on consumer protection policy of the treaty on the functioning of the european union , in order to remedy the fragmented national practices in the area of creditworthiness assessment and ensure equal access to credit for cancer survivors;


### 87. sees an urgent need for a european charter of the rights of cancer patients; calls for this charter to define the rights of cancer patients at every stage of their care pathway , i.e. access to prevention , initial diagnosis and throughout their treatment , and for it to apply equally to all eu citizens , regardless of the country or region in which they live; ### 87. sees an urgent need for a european charter of the rights of cancer patients and to develop a set of indicators for quality assessment based on patient experience (proms/prems); calls for this charter to define the rights of cancer patients at every stage of their care pathway , i.e. access to prevention , initial diagnosis and throughout their treatment , and for it to apply equally to all eu citizens , regardless of the country or region in which they live;


### 87. sees an urgent need for a european charter of the rights of cancer patients; calls for this charter to define the rights of cancer patients at every stage of their care pathway , i.e. access to prevention , initial diagnosis and throughout their treatment , and for it to apply equally to all eu citizens , regardless of the country or region in which they live; ### 87. sees an urgent need for a european charter of the rights of cancer patients; and to create a set of quality assessment indicators based on patients’ experience (proms and prems); calls for this charter to define the rights of cancer patients at every stage of their care pathway , i.e. access to prevention , initial diagnosis and throughout their treatment , and for it to apply equally to all eu citizens , regardless of the country or region in which they live;


### 88. calls for clear policy requirements on paediatric cancer research needs; calls on member states and the commission to redress the unequal allocation of investment to paediatric cancers; considers that a clear and specific eu funding stream should be dedicated to paediatric cancer research and budget allocations earmarked across all relevant eu programmes; ### 88. calls for clear policy requirements on paediatric cancer research needs; calls on member states and the commission to redress the unequal allocation of investment to paediatric cancers; considers that a clear and specific eu funding stream should be dedicated to paediatric cancer research and budget allocations earmarked across all relevant eu programmes; highlights the importance of sustaining international academic research platforms in paediatric cancers , cross-linked and informed by industry-driven research;


### 89. calls on the commission and the member states to focus on ensuring equal access to the best specialist diagnostics and multi-disciplinary treatment for children with cancer , and to improve cancer treatment outcomes in all member states; considers that the professional figure of the paediatric oncologist should be recognised in all member states; ### 89. calls on the commission and the member states to focus on ensuring equal access to the best specialist diagnostics and multi-disciplinary treatment for children with cancer , and to improve cancer treatment outcomes in all member states; considers that the professional figure of the paediatric oncologist should be recognised in all member states; believes that every patient who has experienced cancer as a child or adolescent should receive ongoing medical care and monitoring even after reaching adulthood , and therefore calls for measures to make cooperation between paediatric and adult doctors more flexible; encourages the exchange of knowledge on the course of cancers among children and adolescents;


### 91. stresses the need to strengthen the right to cross-border care for children and aya cancer patients when the best treatment is not available in their country of residence; ### 91. stresses the need to strengthen the right to cross-border care for children and aya cancer patients when the best treatment is not available in their country of residence , and ensure that access to innovation in early clinical trials for relapsed or difficult-to-treat malignancies is covered by the relevant provisions; emphasizes the need for clarification regarding access to cross-border clinical trials , which is not clear in the cross-border healthcare directive;1a


### 91. stresses the need to strengthen the right to cross-border care for children and aya cancer patients when the best treatment is not available in their country of residence; ### 91. stresses the need to strengthen the right to cross-border care for children and aya cancer patients , particularly when the best treatment is not available in their country of residence;


### 92. calls for an ambitious revision of the regulations on paediatric33 and orphan34 medicinal products in order to ensure access to innovative cancer drugs , identify the most important drugs to meet the needs of children with poor prognostic cancers , reduce delays so that children can have faster access to paediatric drugs , and address limited access to certain essential medicines due to drug shortages and the high price of innovative medicines; recommends an increase of 20 % in the available new paediatric cancer drugs by 2027; ### 92. calls for an ambitious revision of the regulations on paediatric33 and orphan34 medicinal products in order to ensure access to innovative cancer drugs , identify the most important drugs to meet the needs of children with poor prognostic cancers , reduce delays so that children can have faster access to paediatric drugs , and address limited access to certain essential medicines due to drug shortages and the high price of innovative medicines; recommends an increase of 20 % in the available new paediatric cancer drugs by 2027 and to increase the accessibility of personalised medicine; calls on the commission to incentivise child specific and first-in-child innovation and to facilitate the repositioning of medicines failing in adults when there is scientific and preclinical rationale , as well as to provide more effective , tailored and flexible incentives to foster the development of medicines for cancer in children , encourage timely paediatric development and reduce delays , such as by means of transferable vouchers , tax credits , and early proportionate rewards allocated incrementally and not exclusively at the end of the supplementary protection certificate (spc); calls on the commission to remove article 11b of the paediatric regulation in the upcoming review to allow paediatric cancer medicine development to be driven by science and the medicine’s mechanism of action;


### 92. calls for an ambitious revision of the regulations on paediatric33 and orphan34 medicinal products in order to ensure access to innovative cancer drugs , identify the most important drugs to meet the needs of children with poor prognostic cancers , reduce delays so that children can have faster access to paediatric drugs , and address limited access to certain essential medicines due to drug shortages and the high price of innovative medicines; recommends an increase of 20 % in the available new paediatric cancer drugs by 2027; ### 92. calls for an ambitious revision of the regulations on paediatric33 and orphan34 medicinal products in order to ensure access to innovative cancer drugs , identify the most important drugs to meet the needs of children with poor prognostic cancers , as well as incentivise the first-in-child development of new paediatric anticancer medicines , support academic research and sme involvement , reduce delays so that children can have faster access to paediatric drugs , and address limited access to certain essential medicines due to drug shortages and the high price of innovative medicines; recommends an increase of 20 % in the available new paediatric cancer drugs by 2027;


### 92. calls for an ambitious revision of the regulations on paediatric33 and orphan34 medicinal products in order to ensure access to innovative cancer drugs , identify the most important drugs to meet the needs of children with poor prognostic cancers , reduce delays so that children can have faster access to paediatric drugs , and address limited access to certain essential medicines due to drug shortages and the high price of innovative medicines; recommends an increase of 20 % in the available new paediatric cancer drugs by 2027; ### 92. calls for an ambitious revision of the regulations on paediatric33 and orphan34 medicinal products in order to ensure access to innovative cancer drugs , identify the most important drugs to meet the needs of children with poor prognostic cancers , reduce delays so that children can have faster access to paediatric drugs , and address limited access to certain essential medicines due to drug shortages and the high price of innovative medicines; recommends an increase of 20 % in the available new paediatric cancer drugs by 2027; calls on the commission , where appropriate in dialogue with the member states , to work on a reimbursement system that favours a real breakthrough accessible innovation for paediatric cancer patients;


### 92. calls for an ambitious revision of the regulations on paediatric33 and orphan34 medicinal products in order to ensure access to innovative cancer drugs , identify the most important drugs to meet the needs of children with poor prognostic cancers , reduce delays so that children can have faster access to paediatric drugs , and address limited access to certain essential medicines due to drug shortages and the high price of innovative medicines; recommends an increase of 20 % in the available new paediatric cancer drugs by 2027; ### 92. calls for an ambitious revision of the regulations on paediatric33 and orphan34 medicinal products in order to ensure access to innovative cancer drugs , identify the most important drugs to meet the needs of children with poor prognostic cancers , reduce delays so that children can have faster access to paediatric drugs , and address limited access to certain essential medicines due to drug shortages and the high price of innovative medicines; recommends an increase of 20 % in the available new paediatric cancer drugs by 2027 , as well as an increase in the accessibility of personalised medicine;


### 93. calls for the creation of an eu-level advisory group of stakeholders dedicated to childhood and aya cancers , which could support the goal-driven and coherent implementation of relevant actions across europe’s beating cancer plan , horizon europe and the pharmaceutical strategy; ### 93. calls for the creation of an eu-level advisory group of stakeholders dedicated to childhood and aya cancers , which could support the goal-driven and coherent implementation of relevant actions across europe’s beating cancer plan , horizon europe and the pharmaceutical strategy and eu4health programme;